--- url: 'https://qubit.capital/blog/uk-series-b-plus-weekly-funding-roundup-week-4-march-2026' title: 'UK Series B+ Weekly Funding Roundup (Mar 16-23, 2026): $57.0M Raised Across 2 Deals' author: name: Sagar Agrawal url: 'https://qubit.capital/blog/author/sagar' date: '2026-03-23T03:18:25+05:30' modified: '2026-03-23T16:07:27+05:30' type: post summary: 'UK Series B+ funding roundup for Mar 16-23, 2026. Mestag Therapeutics raised $38M for immuno-oncology and Chorus Intelligence secured $19M for digital intelligence.' categories: - Weekly Funding Roundup image: 'https://qubit.capital/wp-content/uploads/2026/03/featured-uk-series-bplus-64557.webp' published: true --- # UK Series B+ Weekly Funding Roundup (Mar 16-23, 2026): $57.0M Raised Across 2 Deals Two UK companies at the growth stage pulled in a combined $57 million this week, split between biotech and government technology. The deals reflect a pattern that’s become familiar in British venture capital: deep technical moats built over years of quiet R&D, now reaching the scale where serious capital makes sense. While UK seed-stage startups raised $11.1 million across two deals this week and Series A rounds totalled $61 million across three, the later-stage picture was tighter. Just two companies crossed the Series B+ threshold, but both sit in sectors where the UK has genuine competitive depth. Biotech drug development and public-sector intelligence aren’t flashy, but they’re sticky, high-barrier markets where UK founders keep winning. Weekly Funding Roundup MAR 16-23, 2026 $45M TOTAL RAISED 2DEALS CLOSED 100%SERIES B+ $22.5MAVG DEAL SIZE UKTOP REGION BY STAGE Series B+$45M100% BY SECTOR Mestag TherapeuticsHealthtech / Immuno-Oncology$30M Chorus IntelligenceDeeptech / Government Technology$15M Table of Contents - [1. Mestag Therapeutics Raises $38M For Immuno-Oncology Drug Development](#1-mestag-therapeutics-raises-$38m-for-immuno-oncology-drug-development) [Deal Overview](#deal-overview) - [Investor Profile](#investor-profile) - [Company and Leadership](#company-and-leadership) - [Problem and Opportunity](#problem-and-opportunity) - [Product and Technology](#product-and-technology) - [Use of Proceeds and Vision](#use-of-proceeds-and-vision) - [Market Context](#market-context) - [2. Chorus Intelligence Raises $19M For Law Enforcement Analytics](#2-chorus-intelligence-raises-$19m-for-law-enforcement-analytics) [Deal Overview](#deal-overview-1) - [Investor Profile](#investor-profile-1) - [Company and Leadership](#company-and-leadership-1) - [Problem and Opportunity](#problem-and-opportunity-1) - [Product and Technology](#product-and-technology-1) - [Use of Proceeds and Vision](#use-of-proceeds-and-vision-1) - [Market Context](#market-context-1) - [Lessons For Founders](#lessons-for-founders) ## 1. Mestag Therapeutics Raises $38M For Immuno-Oncology Drug Development ### Deal Overview - **Stage:** Series B+ - **Sector:** Healthtech / Immuno-Oncology - **Geography:** United Kingdom - **Round Size:** £30M (~$38M) ### Investor Profile The round backs Mestag’s transition from preclinical promise to clinical reality. The investor syndicate details haven’t been fully disclosed, but the raise signals strong conviction from backers willing to fund a capital-intensive Phase 1 trial in a competitive oncology space. ### Company and Leadership [Mestag Therapeutics](https://www.mestagtherapeutics.com) is a clinical-stage biotech focused on fibroblast activation protein (FAP) targeted bispecific antibodies. The company has spent years building its pipeline around a single, high-conviction thesis: that targeting the tumour microenvironment through FAP offers a differentiated angle in immuno-oncology. ### Problem and Opportunity Most cancer immunotherapies target the tumour directly or boost the immune system broadly. The tumour microenvironment, the supportive tissue surrounding cancer cells, often undermines these treatments by shielding tumours from immune attack. FAP is highly expressed in this stroma across many solid tumour types, making it a compelling target for therapies that want to strip away the tumour’s defences. ### Product and Technology Mestag’s lead asset is MST-0312, a FAP-targeted bispecific antibody heading into the Phase 1 STARLYS trial. Bispecific antibodies bind two different targets simultaneously, and in this case the design aims to redirect immune cells toward FAP-expressing cells in the tumour stroma. The approach could complement existing checkpoint inhibitors rather than compete with them. ### Use of Proceeds and Vision The £30 million will fund the STARLYS Phase 1 clinical trial and expand Mestag’s clinical operations team. Getting clean safety and early efficacy data from this trial is the next value inflection point. If the data reads well, Mestag would be positioned for a much larger raise or a partnership with big pharma. ### Market Context The global immuno-oncology market exceeded $100 billion in recent years and continues to grow as combination therapies expand indications. FAP-targeted approaches are still relatively early, with a handful of competitors in clinical development. The UK’s biotech ecosystem, with its deep academic links and favourable clinical trial infrastructure, gives companies like Mestag a cost-effective path to early-stage data. ## 2. Chorus Intelligence Raises $19M For Law Enforcement Analytics ### Deal Overview - **Stage:** Series B+ - **Sector:** Deeptech / Government Technology - **Geography:** United Kingdom - **Round Size:** £15M (~$19M) ### Investor Profile Maven led this round. The Edinburgh-based investment firm has a long track record backing UK growth companies, with particular strength in technology businesses selling to the public sector. Maven’s involvement suggests confidence in Chorus’s ability to expand its government contracts and move into adjacent markets. ### Company and Leadership [Chorus Intelligence](https://www.chorusintel.com) builds digital intelligence and investigative platforms used by law enforcement and government agencies. The company has carved out a niche in a market where trust, security clearance, and domain expertise matter far more than slick marketing. ### Problem and Opportunity Law enforcement agencies deal with massive volumes of digital evidence: communications data, financial records, device extractions, social media activity. Investigators often spend more time wrangling data than analysing it. Traditional tools were built for a world with far less data, and they struggle to surface connections across fragmented sources quickly enough for active investigations. ### Product and Technology Chorus provides a platform that ingests, normalises, and cross-references large volumes of structured and unstructured investigative data. The system helps analysts identify patterns, connections, and anomalies that would take human investigators weeks to find manually. The platform is built to meet the stringent security and evidential standards required in criminal proceedings. ### Use of Proceeds and Vision The £15 million will fund product development and geographic expansion. Chorus has an established base with UK police forces and government agencies. The next step is scaling into international law enforcement markets and broadening into adjacent use cases like counter-fraud and regulatory investigation for financial institutions. ### Market Context Government spending on digital investigation tools has increased steadily as cybercrime, fraud, and organised crime grow more complex. The UK govtech market benefits from centralised procurement frameworks that make it easier for proven vendors to scale. Competitors include Palantir at the high end and various point solutions for specific data types. Chorus sits in a sweet spot: sophisticated enough for complex investigations, accessible enough for regional police forces with constrained budgets. ## Lessons For Founders - **Regulatory barriers are moats.** Both Mestag (clinical trial requirements) and Chorus (security clearances, evidential standards) operate in markets where compliance isn’t a cost centre, it’s a competitive advantage. If your product requires government approval or certification, that same friction keeps fast followers out. - **Quiet markets can be large markets.** Neither immuno-oncology drug development nor law enforcement analytics generates much social media buzz. But both represent billions in annual spending with long contract durations and high switching costs. - **UK-specific advantages exist beyond fintech.** The NHS and UK academic hospitals offer cost-effective clinical trial infrastructure. Government procurement frameworks like G-Cloud create scalable sales channels. Founders building for these buyers should lean into the structural advantages rather than defaulting to US-first strategies. - **Growth-stage capital follows proof, not promises.** Both companies raised on demonstrated traction: Mestag with a named clinical candidate ready for trials, Chorus with deployed contracts across UK agencies. At Series B+, investors want to see that the hard technical and commercial work is already done.